CBT 004
Alternative Names: CBT-004Latest Information Update: 15 Feb 2024
At a glance
- Originator Cloudbreak therapeutics
- Class Eye disorder therapies
- Mechanism of Action Platelet-derived growth factor receptor antagonists; Protein kinase inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pinguecula
Most Recent Events
- 21 Dec 2023 Phase-II clinical trials in Pinguecula (In adults, In the elderly) in USA (Ophthalmic) (NCT04884256)
- 18 May 2021 Cloudbreak Therapeutics plans a phase II trial for Pinguecula, in July 2021 (NCT04884256)
- 18 Feb 2021 Cloudbreak Therapeutics receives IND clearance from the US FDA for a phase II trial in vascularised Pinguecula